Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
TRENDS
With Sales of Aricept, Pariet Plummeting, Eisai to Focus on Investment in FY2014 with an Eye to Growth Track in FY2015
Eisai reported its first increase in sales in four years in its settlement of accounts for the fiscal year ended March 2014. Despite slumping sales of the Alzheimer’s disease (AD) treatment Aricept (donepezil) due to the loss of patent protection,…
To read the full story
TRENDS
- Top 10 PHARMA JAPAN Articles of 2024
December 25, 2024
- Top 10 Most-Read PHARMA JAPAN Articles in 2023
December 28, 2023
- Top 10 PHARMA JAPAN Articles in 2022
December 28, 2022
- 15 APIs with 10 Billion Yen-Plus Peak Sales Outlooks Listed in 2021: Jiho Tally
December 28, 2021
- Top 10 PHARMA JAPAN Articles in 2021
December 28, 2021
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…